These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2148149)

  • 1. Age-related antihypertensive and haemodynamic effects of verapamil SR: clinical results and effects on atrial natriuretic peptide.
    Antonicelli R; Tomassini PF; Galletti P; Gambini C; Marini M; Amadio L; Paciaroni E
    Eur J Clin Pharmacol; 1990; 39 Suppl 1():S29-33. PubMed ID: 2148149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Verapamil sustained-release in renal parenchymal hypertension: effect on blood pressure, kidney function, angiotensin II, aldosterone, arginine vasopressin, atrial natriuretic peptide, and lipoproteins.
    Eiskjaer H; Pedersen EB; Rasmussen LM; Jespersen B
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S17-22. PubMed ID: 2475677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of chronic treatment with verapamil on plasma atrial natriuretic peptide levels in young and elderly hypertensive patients.
    Van Bortel LM; Schiffers PM; Böhm RO; Mooij JM; Rahn KH; Struyker Boudier HA
    Eur J Clin Pharmacol; 1990; 39 Suppl 1():S39-40. PubMed ID: 2148150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil.
    Kokkas B; Kotridis P; Karamouzis M; Kanonidis I; Sakadamis G; Dadous G; Haritos S; Kyriakoui P; Theodossiadis ; Papadopoulos PC; Mirtsou-Fidani V; Papadopoulos CL
    Eur J Drug Metab Pharmacokinet; 2002; 27(1):45-8. PubMed ID: 11996326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive efficacy of sustained-release verapamil.
    Zachariah PK; Sheps SG; Oshrain C; Schirger A; Stein WJ
    J Clin Hypertens; 1987 Dec; 3(4):536-46. PubMed ID: 3330987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of sustained-release verapamil: automatic ambulatory blood pressure monitoring.
    Zachariah PK; Sheps SG; Schriger A
    J Clin Hypertens; 1986 Sep; 2(3 Suppl):133S-142S. PubMed ID: 3540223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial natriuretic peptide in human essential hypertension.
    Zachariah PK; Burnett JC; Ritter SG; Strong CG
    Mayo Clin Proc; 1987 Sep; 62(9):782-6. PubMed ID: 2957551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension.
    Hilleman DE; Mohiuddin SM; Lucas BD; Shinn B; Elsasser GN
    Clin Ther; 1993; 15(6):1002-10. PubMed ID: 8111798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favourable interaction of calcium antagonist plus ACE inhibitor on cardiac haemodynamics in treating hypertension: rest and effort evaluation.
    Di Somma S; Carotenuto A; de Divitiis M; Paulucci A; Galderisi M; Cuocolo A; de Divitiis O
    J Hum Hypertens; 1995 Mar; 9(3):163-8. PubMed ID: 7783096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of the effect of short-term treatment with nifedipine and verapamil on blood pressure, plasma atrial natriuretic peptide (ANP) and cyclic guanosine monophosphate (cGMP) in patients with primary arterial hypertension I degree according to WHO].
    Widecka K; Marzecka J; Goździk J; Gruszczyńska M; Ciechanowski K; Czekalski S
    Pol Tyg Lek; 1994 Mar 7-14; 49(10-11):228-30. PubMed ID: 7862584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Plasma levels and noninvasive hemodynamic profile of slow release verapamil (240 mg). A multicenter study].
    Vulpis V; Seccia TM; Ricci S; Pirrelli A
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):227-35. PubMed ID: 7761676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy and tolerability of lisinopril and sustained-release verapamil in older patients with hypertension.
    Weir MR; Lavin PT
    Clin Ther; 1991; 13(3):401-8. PubMed ID: 1659494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effects of slow-release verapamil in relation to plasma concentration in aged hypertensives. A study with continuous monitoring of arterial pressure and electrocardiogram].
    Canonico V; Bonaduce D; De Caprio L; Nicolino A; Forgione L; Petretta M; Rengo F
    G Ital Cardiol; 1990 Oct; 20(10):924-32. PubMed ID: 2090531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The effects of the acute administration of atrial natriuretic peptide on the mechanisms regulating diuresis and natriuresis in the essential hypertension patient].
    Iannettone CM; Strazzulla G; Fabbri G; Piazza E; Valenza T; De Feo ML; Franchi F
    Ann Ital Med Int; 1991; 6(3):273-83. PubMed ID: 1837999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained release verapamil in renal hypertension.
    Eiskjaer H; Pedersen EB; Rasmussen LM; Jespersen B
    Eur J Clin Pharmacol; 1988; 33(6):549-55. PubMed ID: 2966736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.
    Fuenmayor NT; Faggin BM; Cubeddu LX
    Drugs; 1992; 44 Suppl 1():1-11. PubMed ID: 1283570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of verapamil SR 240 mg in essential hypertension: results of a multicentric phase IV study.
    Speders S; Sosna J; Schumacher A; Pfennigsdorf G
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S47-9. PubMed ID: 2475686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verapamil SR and propranolol LA: a comparison of efficacy and side effects in the treatment of mild to moderate hypertension.
    Bochsler JA; Simmons RL; Ward PJ; Chester PC; Latham AN
    J Hum Hypertens; 1988 Mar; 1(4):305-10. PubMed ID: 3065507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive blood pressure monitoring evaluation of verapamil slow-release 240-mg antihypertensive effectiveness.
    Novo S; Alaimo G; Abrignani MG; Longo B; Muratore G; Strano A
    J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S38-41. PubMed ID: 2475683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension.
    White WB; Elliott WJ; Johnson MF; Black HR
    J Hum Hypertens; 2001 Feb; 15(2):135-41. PubMed ID: 11317194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.